Anny M S Cheng1, Dandan Zhao2, Rendian Chen3, Han Y Yin4, Sean Tighe1, Hosam Sheha1, Victoria Casas1, Scheffer C G Tseng5. 1. Ocular Surface Center and Tissuetech Inc., Miami FL, USA. 2. Department of Ophthalmology, Yan'An Hospital of Kunming City, Kunming, Yunnan, China. 3. Department of Ophthalmology, Shenzhen Children's Hospital, Shenzhen, Guangzhou, China. 4. Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA. 5. Ocular Surface Center and Tissuetech Inc., Miami FL, USA. Electronic address: stseng@ocularsurface.com.
Abstract
PURPOSE: To evaluate the clinical efficacy of self-retained cryopreserved amniotic membrane in treating dry eye disease. METHODS: Retrospective review of 10 patients treated with self-retained cryopreserved amniotic membrane (PROKERA® Slim [PKS], Bio-Tissue, Miami, FL) for moderate-to-severe dry eye refractory to conventional maximal medical treatments. Patients' symptoms, use of medications, conjunctival inflammation, corneal staining, and visual acuity were compared before and after treatment. RESULTS: PKS was placed in 15 eyes of the 10 patients for 4.9 ± 1.5 days. All patients experienced symptomatic relief for a period of 4.2 ± 4.7 months (P<.001). Such improvement was accompanied by reduction of OSDI scores (P<.001), use of topical medications (P<.001), conjunctival hyperemia (P<.001), corneal staining (P<.001), and improvement of the visual acuity (P=.06). Linear regression analysis estimated that the optimal duration of PKS placement was 5 days to achieve an average symptom-free duration of 4 months in patients with dry eye. Surprisingly, PKS placement also generated improvement in the contralateral eyes. CONCLUSION: This pilot study suggests that self-retained cryopreserved amniotic membrane via PKS can be used to treat moderate dry eye diseases and warrants further prospective controlled studies.
PURPOSE: To evaluate the clinical efficacy of self-retained cryopreserved amniotic membrane in treating dry eye disease. METHODS: Retrospective review of 10 patients treated with self-retained cryopreserved amniotic membrane (PROKERA® Slim [PKS], Bio-Tissue, Miami, FL) for moderate-to-severe dry eye refractory to conventional maximal medical treatments. Patients' symptoms, use of medications, conjunctival inflammation, corneal staining, and visual acuity were compared before and after treatment. RESULTS: PKS was placed in 15 eyes of the 10 patients for 4.9 ± 1.5 days. All patients experienced symptomatic relief for a period of 4.2 ± 4.7 months (P<.001). Such improvement was accompanied by reduction of OSDI scores (P<.001), use of topical medications (P<.001), conjunctival hyperemia (P<.001), corneal staining (P<.001), and improvement of the visual acuity (P=.06). Linear regression analysis estimated that the optimal duration of PKS placement was 5 days to achieve an average symptom-free duration of 4 months in patients with dry eye. Surprisingly, PKS placement also generated improvement in the contralateral eyes. CONCLUSION: This pilot study suggests that self-retained cryopreserved amniotic membrane via PKS can be used to treat moderate dry eye diseases and warrants further prospective controlled studies.
Authors: Gowri Pachigolla; Pawan Prasher; Mario A Di Pascuale; James P McCulley; John G McHenry; V Vinod Mootha Journal: Eye Contact Lens Date: 2009-07 Impact factor: 2.018
Authors: Dirk Bauer; Susanne Wasmuth; Pia Hermans; Maren Hennig; Karl Meller; Daniel Meller; Nico van Rooijen; Scheffer C G Tseng; Klaus-Peter Steuhl; Arnd Heiligenhaus Journal: Exp Eye Res Date: 2007-06-14 Impact factor: 3.467
Authors: Brian Shafer; Nicole M Fuerst; Mina Massaro-Giordano; Vincent Palladino; Taylor Givnish; Ilaria Macchi; Michael E Sulewski; Stephen E Orlin; Vatinee Y Bunya Journal: Digit J Ophthalmol Date: 2019-06-08
Authors: Marguerite B McDonald; Hosam Sheha; Sean Tighe; Susan B Janik; Frank W Bowden; Amit R Chokshi; Michael A Singer; Seema Nanda; Mujtaba A Qazi; Damon Dierker; Adam T Shupe; Brittany J McMurren Journal: Clin Ophthalmol Date: 2018-04-09
Authors: Thomas John; Sean Tighe; Hosam Sheha; Pedram Hamrah; Zeina M Salem; Anny M S Cheng; Ming X Wang; Nathan D Rock Journal: J Ophthalmol Date: 2017-08-15 Impact factor: 1.909